DUBLIN–(BUSINESS WIRE)–The “Research Report on China’s Gefitinib Market, 2021-2025” report has been added to ResearchAndMarkets.com’s offering.
Gefitinib, originally developed by AstraZeneca, is the world’s first marketed EGFR-TKI for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with sensitive mutations in the EGFR gene, as well as patients with locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy.
AstraZeneca’s gefitinib, with the trade name of Iressa, was approved in the United States in 2003 and in China in 2004. Gefitinib was recommended by the Non-Small Cell Lung Cancer, Version 1.2020, NCCN Clinical Practice Guidelines and the Guidelines of Chinese Society of Clinical Oncology (CSCO) on Treatment of Primary Lung Cancer (2019) as a first-line drug for treatment for patients with EGFR-mutated non-small cell lung cancer, and has been included in the Category B in China’s medical insurance in 2019 and the National Essential Medicines List (2018 edition).
Before the launch of domestic generic drugs in China, the only gefitinib available in the market was the original drug Iressa, with a high price. In 2017, the first generic drug from Qilu Pharmaceutical was approved for marketing in China to compete with Iressa, followed by generic drugs from Chia Tai Tianqing Pharmaceutical and Sichuan Kelun Pharmaceutical, Jiangsu Hengrui Medicine and Yangtze River Pharmaceutical.
In September 2019, in the Chinese government’s centralized drug-procurement, the gefitinib drugs of Qilu Pharmaceutical, Chia Tai Tianqing Pharmaceutical and AstraZeneca were selected at prices of CNY257, CNY450 and CNY547, with the specification of 25 mg (a box of 10 tablets). The price of AstraZeneca’s Iressa was reduced by 76%.
According to the publisher’s market research, before 2019, the sales value of China’s gefitinib market kept growing year by year. In 2019, the average price of gefitinib decreased significantly due to the Chinese government’s centralized drug-procurement program. Therefore, although the sales volume of gefitinib in China increased in 2019, its sales value declined greatly.
In 2020, both of them decreased due to the COVID-19 outbreak, which impacted the proper function of Chinese healthcare institutions. The sales value of gefitinib in China was approximately CNY312 million (USD48.1 million) in 2020, with a CAGR of about 1.3% from 2016 to 2020.
According to the publisher’s market research, although AstraZeneca’s original drug, Iressa, is much more expensive than generic drugs from local Chinese companies, it still held more than 70% share of the market in 2020 in terms of sales value.
The publisher expects that from 2021 to 2025, China’s gefitinib market will show a recovery growth in both sales volume and value due to the effective control of COVID-19 and the resumption of proper operation of healthcare facilities.
The publisher expects that, from 2021 to 2025, new cases of lung cancer in China will continue to grow as a result of environmental pollution and poor lifestyles. And with the growing income of Chinese residents, they are able to pay more for medical expenses. Therefore, China’s alectinib market is expected to grow in both sales volume and value during this period.
Topics Covered:
- Impact of COVID-19 on China’s Gefitinib Market
- Development Environment of Gefitinib in China
- Sales Volume of Gefitinib in China
- Sales Volume and Value of Gefitinib in China by Region
- Major Gefitinib Manufacturers in China and Their Market Shares
- Sales Price of Gefitinib in China
- Major Gefitinib Producers in China
- Prospects of China’s Gefitinib Market, 2021-2025
Key Topics Covered:
1 Relevant Concepts of Gefitinib
1.1 Indications of Gefitinib
1.2 Development of China’s Gefitinib Market
1.3 Governmental Approval of Gefitinib in China
1.4 The Impact of COVID-19 on China’s Gefitinib Market
2 Sales of Gefitinib in China, 2016-2020
2.1 Sales Value
2.1.1 Sales Value in China
2.1.2 Sales Value in China by Region
2.2 Sales Volume
2.2.1 Sales Volume in China
2.2.2 Sales Volume in China by Region
2.3 Sales of Gefitinib in China by Dosage Form, 2016-2020
2.3.1 Tablets
2.3.2 Other Dosage Forms
3 Analysis of Major Gefitinib Manufacturers in China, 2020
3.1 Analysis of Market Share
3.1.1 Market Share of Manufacturers by Sales Value
3.1.2 Market Share of Manufacturers by Sales Volume
3.2 AstraZeneca AB
3.2.1 Company Profile
3.2.2 Sales of Gefitinib in China
3.3 Qilu Pharmaceutical (Hainan) Co., Ltd.
3.3.1 Company Profile
3.3.2 Sales of Gefitinib in China
3.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3.4.1 Company Profile
3.4.2 Sales of Gefitinib in China
3.5 Yangtze River Pharmaceutical Group
3.5.1 Company Profile
3.5.2 Sales of Gefitinib in China
4 Sales Price of Gefitinib of Different Companies in China, 2020-2021
4.1 AstraZeneca AB (Iressa)
4.2 Qilu Pharmaceutical (Hainan) Co., Ltd. (Yiruike)
4.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Jizhi)
4.4 Yangtze River Pharmaceutical Group
5 Prospects of China’s Gefitinib Market, 2021-2025
5.1 Influencing Factors for the Market Development
5.1.1 The Impact of COVID-19 on the Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
For more information about this report visit https://www.researchandmarkets.com/r/csop5u
The content is by Business Wire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.
